Medicis Life Sciences

Medicis Life Sciences is a biopharmaceutical company specializing in the development of prescription-grade cannabinoid-based medicines. The company utilizes a proprietary extraction and purification platform to develop botanical drug candidates that target the endocannabinoid system. Its lead programs focus on chronic pain management and refractory epilepsy, aiming to provide standardized, clinically-validated alternatives to traditional medical cannabis. Medicis operates with a global footprint, maintaining research and corporate facilities in Switzerland and India. The company's approach combines botanical expertise with rigorous pharmaceutical development to address significant unmet needs in neurology and oncology.